Background: Around 10 million people worldwide contract tuberculosis every year.
According to the World Health Organization (WHO), approximately one-quarter of the world's …

Introduction: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory
approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

The emergence of data from clinical trials of biologics, the approval of new biologics, and
our improved understanding of psoriasis pathogenesis have increased the therapeutic …

Psoriasis is a common disease, which has a considerable impact on the healthcare system.
Therefore, appropriate use of therapeutic resources is very important. Management of …

Tuberculosis (TB) still represents an important issue for public health in underdeveloped
countries, but the use of antitumor necrosis factor agents (anti-TNF) for the treatment of …

Tuberculosis is an infectious disease with a major global impact, ranked in the top 10
mortality causes worldwide. In an immunocompetent individual, the host defence …

Objective Immunosuppressed individuals are at a high risk of latent tuberculosis infection
(LTBI) and clinical practice guidelines for the screening and management of LTBI in at-risk …